MARATTO

article · PLoS ONE

Facilitators, barriers, and strategies for the implementation of peer-led tuberculosis active case finding among people who use drugs in Dar es Salaam, Tanzania

In plain language

Tuberculosis remains a leading cause of infectious disease mortality globally, with millions of cases going undiagnosed each year. People who use drugs face high rates of tuberculosis, yet little data exists on their perspectives regarding active case finding. A qualitative study in Dar es Salaam, Tanzania, assessed facilitators and barriers to peer-led active case finding among three groups of people who use drugs. Findings revealed strong acceptability for peer-delivered screening services. Service delivery could be further optimised through mobile diagnostics, integrated methadone and tuberculosis care, enhanced screening tools, and monetary incentives for peers. Key challenges included low adherence to infection control due to stigma around wearing masks, high population mobility, and fear that anti-tuberculosis medication triggers opiate withdrawal symptoms. Community-driven, peer-supported approaches offer strong potential if these operational barriers and clinical interactions are addressed.

Key takeaways

  • Peer-led tuberculosis active case finding is highly acceptable among people who use drugs.
  • Integrated methadone and tuberculosis care, mobile diagnostics, and peer financial incentives facilitate screening delivery.
  • Stigma surrounding face masks and misunderstandings about preventive therapy reduce compliance with infection control.
  • Fears of opiate withdrawal symptoms caused by anti-tuberculosis medications deter individuals from initiating treatment.
  • Screening can be strengthened by incorporating symptom-independent tests such as chest X-rays to counter masking by drug use symptoms.

Why it matters

People who use drugs are at high risk of tuberculosis but are often missed by conventional healthcare systems. Understanding their perspectives allows public health programmes to design targeted, peer-led screening interventions. Addressing specific challenges such as medication interactions and mask-related stigma can significantly improve diagnosis, care engagement, and treatment completion in this vulnerable population.

Commercialisation angle

The findings inform operational design for public health providers, non-governmental organisations, and mobile diagnostic implementers. They identify clear needs for adapted screening protocols, integrated mobile clinics, and opiate-compatible or shorter anti-tuberculosis regimens. This represents applied operational research ready to guide public health service delivery and community intervention models rather than a commercial product pathway.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

BACKGROUND: Globally, tuberculosis (TB) is the leading cause of death from a single infectious agent. In 2023, an estimated 2.7 million cases of TB were undiagnosed or unreported. To address missing cases, the World Health Organization recommends systematic screening for TB. This is synonymous to active case finding (ACF) and involves provider-initiated screening and testing for TB. Despite the high incidence and prevalence of TB among people who use drugs (PWUD), there is a significant gap in data, on their perspectives, regarding the implementation of TB ACF services. This study aimed to explore facilitators and barriers to implementing peer-led TB ACF, as perceived by both, current and potential service users. METHODS: We conducted in-depth interviews among purposively selected adult PWUD in Dar-es-Salaam region, Tanzania. Study participants included: (1) peer PWUD with prior history of illicit drug use and medication-assisted treatment (MAT) (n = 10), (2) current medication-assisted treatment service users receiving clinic-based daily methadone (n = 8), and (3) community PWUD not on MAT recruited from various community locations (n = 4). All peer PWUD were experienced in TB ACF. Thematic content analysis was utilized with the support of NVivo12. RESULTS: Our findings are presented into two categories: individual and structural, with three main themes pertaining to peer-led TB ACF: (1) facilitators (2) facilitators for targeted improvement and optimization and (3) barriers. A critical facilitator was the acceptability of peer PWUD in providing TB ACF services. Key facilitators for targeted improvement and optimization included the TB screening tool, mobile TB diagnostic services, integrated methadone/TB services, and monetary incentives to peer PWUD. Barriers included inadequate adherence to infection prevention and control (IPC) measures when providing TB ACF services resulting in a reluctance to wear face masks due to stigma, misconceptions that prior TB preventive therapy among peers negates their need for continued IPC adherence, high mobility of PWUD and the fear of withdrawal symptoms associated with the use of anti-TB medication. Due to this fear, many PWUD preferred not to take anti-TB, as they were concerned about the potential severity of withdrawal symptoms. CONCLUSION: Our findings highlight the crucial role of peer-led approaches in enhancing TB ACF among PWUD. Peer acceptance as service providers highlights the potential of community-driven interventions. Strengthening facilitators and addressing challenges is key to optimizing these services. Future research should explore the feasibility of providing peer-supported TB diagnosis and treatment services at friendly drop-in centers. RECOMMENDATIONS: 1. Strengthen mobile diagnostic services by increasing their frequency and coverage, enabling timely diagnosis and treatment. 2. Enhance the TB symptom screening tool by including a symptom-independent test, such as a chest X-ray, as the symptoms of illicit drug use can mask and mimic TB symptoms making diagnosis challenging. 3. Address stigma and misconceptions through peer-led education and awareness campaigns that utilize audio-visual materials tailored to PWUD. This will promote adherence to IPC measures and create a more supportive environment for TB ACF activities. 4. Use anti-TB with minimal interactions with opiates or shorter TB treatment regimens to prevent withdrawal symptoms and improve adherence.

Research topics

  • Tuberculosis Research and Epidemiology
  • HIV, Drug Use, Sexual Risk
  • HIV/AIDS Research and Interventions

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1371/journal.pone.0310069

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.